FDA Gives Breakthrough Therapy Designation to Post-Neoadjuvant T-DXd for HER2+ Early …

… news release. ¹ “We look forward to working with the FDA with the goal of bringing [T-DXd] to the post-neoadjuvant setting of HER2-positive early …